Bad Times For Breakthrough Drugs Targeting Chemo Complications; Submissions From BMS, Merck
Executive Summary
The latest news about applications under FDA review, from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
Can Can-Fite’s Piclidenoson Put Up A Fight In Psoriasis?
Can-Fite’s A3AR agonist was inferior to Amgen’s Otezla by most efficacy measures, while Bristol Myers Squibb’s competing deucravacitinib is closer to approval and did beat Otezla.
Four Major Approval Decisions To Watch Out For In Q2
Having looked at four prominent drug candidates which are expecting important top-line data this quarter, with the help of Biomedtracker's Q2 Outlook Report, we take a look at four other assets that could soon break into the US market, from infectious diseases to diabetes.
TG Therapeutics Ukoniq’s Future In Doubt Amidst Scrutiny Of P13K Inhibitor Accelerated Approvals
Advisory committee review of combo with ublituximab may provide forum to discuss the Phase III data showing increased risk of death that prompted US FDA safety alert.